Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. (NYSE American: DSS) generates news across a wide range of sectors, reflecting its role as a multinational company with diversified business lines in packaging, biohealth innovation, financial services, alternative trading, and real estate. The company’s press releases and regulatory disclosures highlight strategic transactions, capital markets developments, operational milestones, and portfolio optimization efforts.
News about DSS often covers corporate strategy and portfolio management, including spin-offs, asset sales, and transactions involving key subsidiaries. Examples include the sale of the Celios air purification asset to Impact BioMedical Inc., as well as a definitive merger agreement under which Impact BioMedical will be acquired through a reverse merger with Dr. Ashleys Limited, resulting in a new public company. These items illustrate DSS’s stated approach of unlocking value by advancing subsidiaries toward independent public listings and other exit opportunities.
Investors and followers of DSS can also expect updates on financial performance and corporate actions. The company reports on revenue trends, cash flow improvements, debt reduction, and asset monetization, such as the sale of a real estate facility and growth in rental income. Leadership communications, including letters to shareholders and announcements of executive appointments, provide additional context on strategic priorities, cost reduction initiatives, and the focus on core growth verticals.
Because DSS has subsidiaries in securities and investment management, its news flow includes developments at entities like Sentinel Brokers Company, Inc. and AmericaFirst Funds. These updates may involve regulatory approvals, such as FINRA authorization for underwriting activities, changes to mutual fund boards, and expansion of capital markets capabilities. For a comprehensive view of DSS-related developments, readers can use this news page to follow corporate strategy, subsidiary activity, and key financial and regulatory events over time.
DSS (NYSE: DSS) announced a proposed public offering of its common stock to be sold by the company, with net proceeds intended for general corporate and working capital purposes. The offering is subject to market conditions and may not be completed on a specific timeline or at specific terms.
Aegis Capital Corp. is sole book-running manager on a firm commitment basis. The offering will be made under an effective shelf registration statement (Form S-3 No. 333-281974, declared effective Nov 5, 2024), and a final prospectus supplement and accompanying prospectus will be filed with the SEC.
DSS, Inc. (NYSE American: DSS) has announced that its subsidiary, Impact BioMedical Inc., will merge with Dr. Ashleys Limited, a global pharmaceutical company. The reverse merger will create a new entity listed on NYSE American as "Dr Ashleys Limited". Following various equity conversions, DSS will hold 4.80% ownership in the combined company.
The merger combines Dr. Ashleys' pharmaceutical manufacturing and commercialization capabilities with Impact BioMedical's innovation platform. The transaction aligns with DSS's strategy of unlocking shareholder value through subsidiary development and monetization. The merged company will be managed by Dr. Ashleys' team, pending shareholder and regulatory approvals.
DSS reported strong Q1 2025 financial results, demonstrating significant progress in its financial repositioning strategy. The company achieved 28% year-over-year revenue growth, driven by a 30% increase in printed product sales and an impressive 78.5% growth in rental income from $400,000 to $714,000. Key financial highlights include the successful sale of its Plano, TX facility for $9.5 million, debt reduction of over $8 million, and a $1.5 million equity capital raise through Impact BioMedical. Operating cash flow improved, with net cash used in operations decreasing from $2.15 million in Q1 2024 to $1.64 million in Q1 2025.
Sentinel Brokers Company, a subsidiary of DSS (NYSE American: DSS), has received FINRA approval to act as an underwriter and selling group member for corporate securities offerings. This regulatory milestone enables Sentinel to participate in IPOs, follow-on offerings, and various corporate financing transactions.
Founded in 1996, Sentinel has established itself in institutional fixed income trading and expanded to equity market-making in 2021. The new FINRA approval allows the company to provide a comprehensive suite of services across multiple asset classes, enhancing its position in capital markets and ability to support corporate issuers and institutional clients throughout the capital formation process.
DSS (NYSE American: DSS) has announced the sale of its Celios® air purification technology to Impact BioMedical (NYSE American: IBO) in an all-equity transaction valued at $1.15 million. The strategic divestiture is part of DSS's portfolio optimization strategy to focus on core growth areas.
Celios® features a patented three-stage filtration system capable of removing ultrafine particles as small as 10 nanometers, enhancing indoor air quality and reducing airborne health risks. According to CEO Jason Grady, this transaction allows DSS to streamline its holdings and concentrate on business segments with stronger long-term synergies.
DSS, Inc. (NYSE American: DSS) announced significant operational improvements in their Q3 2024 financial performance. The company reported an 8% decrease in operating loss for both the three and nine-month periods ended September 30, 2024, compared to 2023. The net loss declined by 52% ($17.3 million) year-over-year for the nine months and 15% ($1.0 million) for the three-month period.
Cash flow from operations improved by $11.8 million (56%), with net cash position strengthening from $6.9 million to $11.8 million. The company completed the spin-off of Impact BioMedical in September 2024. Under new Interim CEO Jason Grady, DSS plans to reduce costs by 15-20% in the upcoming fiscal year, focus on expanding Premier Packaging, and enhance R&D initiatives in biomedical technologies and sustainable packaging.
DSS, Inc. (NYSE American: DSS) celebrates the successful IPO of Impact BioMedical Inc. (NYSE American: IBO), a company focused on healthcare and wellness solutions. The IPO was priced at $3.00 per share for 1,500,000 shares, with trading beginning on September 16, 2024 on the NYSE American Market. This milestone enhances shareholder value for DSS investors.
Key points:
- DSS distributed 4 shares of Impact BioMedical for every 1 DSS share held on July 10, 2023
- Underwriters received warrants to purchase up to 75,000 shares (or 86,250 if over-allotment is exercised)
- Warrants are exercisable at 125% of IPO price from 9 months after offering until the 3rd anniversary
Jason Grady, Interim CEO of DSS, expressed pride in Impact BioMedical's success and its alignment with DSS's commitment to shareholder returns.
AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), announced changes to its Board of Trustees. Three independent directors resigned on August 9, 2024, and three new directors were elected by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson, and Mark Gronet.
The new directors bring extensive experience in asset management, risk management, investment operations, and sales. Dr. Datta has a background in finance and operations, Robinson is a real estate industry veteran, and Gronet has expertise in institutional sales and human resources. These appointments aim to enhance the Trust's expertise and support its growth and success in the evolving investment landscape.
DSS, Inc. (NYSE American: DSS) has appointed Jason Grady as Interim CEO, effective August 23, 2024. Grady, previously COO, succeeds Frank D. Heuszel, who is transitioning to a leadership role at Impact Biomedical, a former DSS subsidiary. With over 25 years of executive experience, Grady has held key positions within DSS, including CEO of DSS Biohealth Holdings and President of Premier Packaging
Grady aims to lead DSS into its next growth phase, focusing on operational efficiency, revenue generation, and reducing cash burn. He acknowledges past challenges and is committed to enhancing shareholder value. This leadership change marks a pivotal moment for DSS as it navigates the evolving business landscape and strives to turn challenges into opportunities.
Summary not available.
FAQ
What is the current stock price of Dss (DSS)?
What is the market cap of Dss (DSS)?
